This report examines the drug development landscape for childhood cancer, identifying scientific, logistical, economic and ethical challenges that are unique to pediatric cancer drug development.
As Congress and the administration consider changes to federal spending that could severely cut Medicaid funding and impact state budgets, some facts are getting lost in the debate.
ACS CAN has endorsed the Give Kids A Chance bill and has joined the Alliance for Childhood Cancer in calling on Congress to pass this legislation. The bill would restore import incentives to developing drugs for children with cancer.
